FDA opens Operation TrialBlazer for applications, hoping to reshore early trials

Summary

The FDA launched Operation TrialBlazer to reduce clinical hold risks and accelerate first-in-human trials in the U.S. by partnering drug sponsors with qualified research institutions, with applications due by October 30, 2026.